Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus - PubMed (original) (raw)
Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus
H Q Wu et al. Eur J Pharmacol. 2000.
Abstract
The synthetic compound 4-chlorokynurenine has been shown to be enzymatically transaminated to the selective glycine(B) receptor antagonist 7-chlorokynurenate. Since 4-chlorokynurenine, in contrast to 7-chlorokynurenate, readily penetrates the blood-brain barrier, the present study evaluated its neuroprotective properties after systemic administration in rats. Intrahippocampal injection of the NMDA receptor agonist quinolinate (15 nmol/l microl) was used as the neurotoxic paradigm. Serum and hippocampal tissue measurements confirmed that 4-chlorokynurenine serves as an effective pro-drug of 7-chlorokynurenate both in the periphery and in the brain. These studies and complementary hippocampal microdialysis experiments compared the effects of single and repeated injections of 4-chlorokynurenine (50 or 200 mg/kg, intraperitoneal (i.p.), 10 min prior to an intrahippocampal quinolinate injection; or 50 mg/kg, i.p., 10 min before and 30, 120 and 360 min after quinolinate). With the multiple-dosing regimen, extracellular 7-chlorokynurenate levels in the hippocampus reached a maximum of approximately 750 nM 7 h after quinolinate and gradually decreased with a half-life of about 3 h. In contrast, a single injection of 200 mg/kg 4-chlorokynurenine resulted in a considerably shorter rise in extracellular 7-chlorokynurenate without yielding higher peak levels. In separate animals, repeated treatment with 50 mg/kg 4-chlorokynurenine, but not a single injection of 200 mg/kg of the pro-drug, provided total protection against quinolinate-induced excitotoxicity. These data suggest that a prolonged and functionally relevant blockade of hippocampal glycine(B) receptors can be achieved after the systemic administration of 4-chlorokynurenine.
Similar articles
- In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P, Wu HQ, Schwarcz R. Guidetti P, et al. Exp Neurol. 2000 May;163(1):123-30. doi: 10.1006/exnr.1999.7284. Exp Neurol. 2000. PMID: 10785450 - Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo.
Lee SC, Schwarcz R. Lee SC, et al. Neurosci Lett. 2001 May 25;304(3):185-8. doi: 10.1016/s0304-3940(01)01791-8. Neurosci Lett. 2001. PMID: 11343833 - Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K. Harris CA, et al. Br J Pharmacol. 1998 May;124(2):391-9. doi: 10.1038/sj.bjp.0701834. Br J Pharmacol. 1998. PMID: 9641558 Free PMC article. - Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo.
Wu HQ, Salituro FG, Schwarcz R. Wu HQ, et al. Eur J Pharmacol. 1997 Jan 14;319(1):13-20. doi: 10.1016/s0014-2999(96)00829-1. Eur J Pharmacol. 1997. PMID: 9030892 - Neuropharmacology of quinolinic and kynurenic acids.
Stone TW. Stone TW. Pharmacol Rev. 1993 Sep;45(3):309-79. Pharmacol Rev. 1993. PMID: 8248282 Review.
Cited by
- Kynurenines in the CNS: recent advances and new questions.
Vécsei L, Szalárdy L, Fülöp F, Toldi J. Vécsei L, et al. Nat Rev Drug Discov. 2013 Jan;12(1):64-82. doi: 10.1038/nrd3793. Epub 2012 Dec 14. Nat Rev Drug Discov. 2013. PMID: 23237916 Review. - Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
Kincses ZT, Vecsei L. Kincses ZT, et al. CNS Neurosci Ther. 2011 Oct;17(5):345-67. doi: 10.1111/j.1755-5949.2010.00150.x. Epub 2010 Apr 23. CNS Neurosci Ther. 2011. PMID: 20438581 Free PMC article. Review. - Kynurenines in Parkinson's disease: therapeutic perspectives.
Zádori D, Klivényi P, Toldi J, Fülöp F, Vécsei L. Zádori D, et al. J Neural Transm (Vienna). 2012 Feb;119(2):275-83. doi: 10.1007/s00702-011-0697-3. Epub 2011 Aug 20. J Neural Transm (Vienna). 2012. PMID: 21858430 Review. - Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
Bohár Z, Toldi J, Fülöp F, Vécsei L. Bohár Z, et al. Int J Mol Sci. 2015 Apr 29;16(5):9772-93. doi: 10.3390/ijms16059772. Int J Mol Sci. 2015. PMID: 25938971 Free PMC article. Review. - The Role of Serine Racemase in the Pathophysiology of Brain Disorders.
Coyle JT, Balu DT. Coyle JT, et al. Adv Pharmacol. 2018;82:35-56. doi: 10.1016/bs.apha.2017.10.002. Epub 2017 Nov 29. Adv Pharmacol. 2018. PMID: 29413527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources